ArticleBMC ophthalmology2026
Treatment adherence in chronic uveitis: What does the MARS-5 tell us?
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate medication adherence among patients with chronic uveitis using the five-item Medication Adherence Report Scale (MARS-5) and to identify the difficulties and barriers affecting adherence.
methodsA single-center, cross-sectional study was conducted with 99 adult patients diagnosed with chronic uveitis. Participants completed sociodemographic and disease-related questionnaires, the MARS-5 scale, and if scoring below 25 a nine-item adherence barrier questionnaire. Descriptive statistics and appropriate parametric or non-parametric tests were used to analyze relationships between adherence and sociodemographic or clinical variables.
resultsThe mean age of the participants was 32.6 ± 8.7 years, and the mean total MARS-5 score was 22.9 ± 2.3. Adherence levels were perfect in 38.4% of patients, high in 48.5%, and moderate in 13.1%; no participants demonstrated poor adherence. Male patients exhibited significantly lower MARS-5 scores than females (p < 0.001). A moderate positive correlation was found between adherence and duration of medication use (r = 0.447, p = 0.012). The item most frequently indicating non-adherence was “forgetting to take medication.” The most commonly reported barriers were fear of side effects (34.4%) and medication-related difficulties such as unpleasant taste, tablet size, or injection-related concerns (26.2%).
conclusionMedication adherence among chronic uveitis patients was generally high but influenced by sociodemographic and behavioral factors. Both intentional and unintentional non-adherence were observed, emphasizing the need for individualized adherence-support strategies, improved patient education, and enhanced communication to optimize long-term disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.